RE:RE:RE:RE:RE:Merck to buy Prometheus Bio....Further to my previous message:
The statistical test to be used is likely the difference in the medians (means would be easier) over the variance. The medians would likely be the result of this arm compared to the standard of care outcome for that arm. If there is very little variance, then the number is bigger. I cannot eyeball the variance from what is shown on the ONCY web site.
But if there are more complete responses (tumor gone) then the case could be made that accelerated approval is merited to continue the process is what would be stage 3-4 tests by selling the product.
Remember, pela does not cause adverse health effects. For all we know, it could lessen adverse health effects of combos compared to without it (I am guessing here).